Multi-Omics Data Integration Reveals New Targets In RAS-Mutant Cancers Resistant to KRASG12C Inhibition

Time: 3:30 pm
day: Day Two Track E


  • In Vivo CRIPSR screens in RAS mutant cell lines models reveal new vulnerabilities for ERK/MAPK addicted cancers
  • KRASG12Ci Resistant cell lines models can be leveraged to reveal treatment emergent vulnerabilities in these cancers
  • Co-Targeting of the RAS and Hippo pathway might provide a rationale therapeutic approach to overcome resistance to RAS targeted therapies with Biomarker opportunities discussed